EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Potential Therapeutic Role of Bruton Tyrosine Kinase Inhibition in Neurodegenerative Diseases

Francesco D’Egidio, Housem Kacem, Giorgia Lombardozzi, Michele d’Angelo, Annamaria Cimini, Vanessa Castelli

Applied Sciences · 24.07.2025 · 15 (15) · 8239

DOI: 10.3390/app15158239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Sciences, online erschienen am 24.07.2025. Verfasst von Francesco D’Egidio und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruton Tyrosine Kinase (BTK) has emerged as a critical mediator in the pathophysiology of neuroinflammation associated with neurodegenerative diseases. BTK, a non-receptor tyrosine kinase predominantly expressed in cells of the hematopoietic lineage, modulates B-cell receptor signaling and innate immune responses, including microglial activation. Recent evidence implicates aberrant BTK signaling in the exacerbation of neuroinflammatory cascades contributing to neuronal damage in disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, ischemic stroke, and Huntington’s disease. Pharmacological inhibition of BTK has shown promise in attenuating microglial-mediated neurotoxicity, reducing pro-inflammatory cytokine release, and promoting neuroprotection in preclinical models. BTK inhibitors, originally developed for hematological malignancies, demonstrate favorable blood–brain barrier penetration and immunomodulatory effects relevant to central nervous system pathology. This therapeutic approach may counteract detrimental neuroimmune interactions without broadly suppressing systemic immunity, thus preserving host defense. Ongoing clinical trials are evaluating the safety and efficacy of BTK inhibitors in patients with neurodegenerative conditions, with preliminary results indicating potential benefits in slowing disease progression and improving neurological outcomes. This review consolidates current knowledge on BTK signaling in neurodegeneration and highlights the rationale for BTK inhibition as a novel, targeted therapeutic strategy to modulate neuroinflammation and mitigate neurodegenerative processes.

Zitieren

APA

D’Egidio, F., Kacem, H., Lombardozzi, G., d’Angelo, M., Cimini, A., & Castelli, V. (2025). The Potential Therapeutic Role of Bruton Tyrosine Kinase Inhibition in Neurodegenerative Diseases. Applied Sciences, 15(15), 8239. https://doi.org/10.3390/app15158239

Vancouver

D’Egidio F, Kacem H, Lombardozzi G, d’Angelo M, Cimini A, Castelli V. The Potential Therapeutic Role of Bruton Tyrosine Kinase Inhibition in Neurodegenerative Diseases. Applied Sciences. 2025;15(15):8239. doi:10.3390/app15158239

BibTeX
@article{DEgidio2025,
  author = {D’Egidio, Francesco and Kacem, Housem and Lombardozzi, Giorgia and d’Angelo, Michele and Cimini, Annamaria and Castelli, Vanessa},
  title = {The Potential Therapeutic Role of Bruton Tyrosine Kinase Inhibition in Neurodegenerative Diseases},
  journal = {Applied Sciences},
  year = {2025},
  volume = {15},
  number = {15},
  pages = {8239},
  doi = {10.3390/app15158239}
}
Kostenlos starten →